Quantitative analysis of breast tumours aided by three-dimensional photoacoustic/ultrasound functional imaging

Meng Yang1,5, Lingyi Zhao2,5, Fang Yang3, Ming Wang1, Na Su1, Chenyang Zhao1, Yang Gui1, Yao Wei1, Rui Zhang1, Jianchu Li1, Tao Han2, Xujin He3, Lei Zhu3, Huanwen Wu4, Changhui Li2,5 & Yuxin Jiang1,5 ✉

In this pilot study, we explored a quantitative method to analyse characteristics of breast tumours using 3D volumetric data obtained from a three-dimensional (3D) photoacoustic/ultrasound (PA/US) functional imaging system. Imaging results from 24 Asian patients with maximum tumour diameters less than 2 cm, including 8 benign tumours, 16 T1 stage invasive breast cancers (IBCs), and 22 normal breasts, were analysed. We found that the volumetric mean oxygenation saturation (SO2) in tumour regions of T1 stage IBCs was 7.7% lower than that of benign tumours (P = 0.016) and 3.9% lower than that of healthy breasts (P = 0.010). The volumetric mean SO2 in tumour surrounding regions of T1 stage IBCs was 4.9% lower than that of benign tumours (P = 0.009). For differentiating T1 stage IBCs and benign tumours, with a cut-off SO2 value of 78.2% inside tumours, we obtained a sensitivity of 100%, a specificity of 62.5%, and an AUC of 0.81; with a cut-off SO2 value of 77.9% in regions surrounding tumours, we obtained a sensitivity of 100%, a specificity of 75% and an AUC of 0.84. Our preliminary results demonstrate that 3D PA/US functional imaging has the potential to provide valuable quantitative physiological information that may be useful for the detection and evaluation of breast tumours.

Breast cancer has become the most common cancer among the female population worldwide and accounted for approximately 14.6% of all new cancer cases in the United States in 20164. Early detection of breast cancer (T1 stage) is of vital importance since it contributes to lower mortality and lower burdens on society as a whole6. X-ray mammography and breast ultrasonography (US) are the two most widely used modalities for breast cancer screening7. Mammography has superior sensitivity to microcalcifications8, and US is effective for detecting invasive cancer in dense breasts9. Although X-ray and US imaging have played important roles in clinical diagnosis of breast cancers, new methods and technologies are desired to further improve the diagnostic accuracy to reduce the unnecessary biopsy of benign lesions8. As a novel imaging modality, photoacoustic (PA) breast imaging has received much attention in the past decade. PA imaging combines the advantages of both high-resolution ultrasonic anatomic detection and the high contrast of optically absorbing tissues such as vascular networks7–9, which are closely related to tumour angiogenesis and metastasis10,11. Furthermore, with two or more optical wavelengths, PA imaging can provide functional information such as the oxygen saturation (SO2), which is important for revealing tumour metabolism and therapeutic response12. Owing to these unique characteristics, PA breast imaging has made significant progresses13–17.

The integration of PA imaging with traditional handheld US systems has gained much interest in clinical studies since the operators are familiar with the imaging procedure and can obtain both functional and morphological information18–22. Two-dimensional (2D) PA/US imaging based on handheld US systems has showed promising
progress in clinical breast imaging\textsuperscript{13,14}. A multi-central study that enrolled 2105 subjects showed that PA/US increases the specificity of breast mass assessment compared with US alone\textsuperscript{13}. Another study employing multispectral PA/US imaging resolved breast cancer features with high resolution and revealed patterns not offered by other radiologic modalities\textsuperscript{14}. Although these pioneer PA clinical studies have obtained promising results, they mostly rely on 2D imaging and have not yet provided a robust quantitative analysis method for early breast cancer detection. Instead, with the aid of 3D anatomy information of tumours gained from 3D US imaging, 3D PA/US imaging can provide volumetric functional information such as volumetric mean SO$_2$ value in both tumour regions and tumour surrounding regions. Without the need to select 2D B-scan slices, variance can be reduced, and quantitative analysis can then be carried out with more stability. Furthermore, based on 3D PA/US imaging, 3D morphological distribution of vessels can be reconstructed, which may allow a more comprehensive assessment of blood supply in lesions. The feasibility of 3D PA/US imaging has been verified by either combining a traditional handheld US system with a scanning linear probe or by utilizing a 2D array\textsuperscript{21–23}, although few systems have been applied to clinical trials of breast imaging.

In this study, we performed a pilot clinical study of a self-developed 3D PA/US imaging system. The purpose is to explore the potential value of quantitative analysis with 3D PA/US functional imaging in patients with breast tumours. Specifically, we aimed to explore the potential of 3D PA/US functional imaging to aid traditional US imaging in achieving a higher diagnostic accuracy. The presented imaging method can provide complementary functional information, such as SO$_2$, for US imaging. In this work, we did a pilot study to assess the potential value of the volumetric mean SO$_2$ in differentiating benign breast tumours from malignant ones based on 3D PA/US functional imaging.

Materials and Methods

Our study protocol was approved by the institutional ethics committee of Peking Union Medical College Hospital. All research was performed in accordance with relevant regulations. Written informed consent was obtained from all participants.

PA/US dual mode functional 3D imaging system. The dual-modality system (see Supplementary Fig S1) in this study is based on a high-end clinical US machine (Resona 7, Mindray Bio-Medical Electronics Co., Ltd.)\textsuperscript{20}, which is capable of performing parallel data acquisition required by PA imaging. Results of PA imaging were reconstructed online with the delay and sum algorithm. The clinical linear probe (L9–3U, Mindray Bio-Medical Electronics Co., Ltd.) has 192 elements, each element has a size of 0.2 mm and the central frequency is 5.8 MHz. The laser source is an OPO tunable laser (Spotlight 600-OPO, Innolas laser GmbH), which generates 700–850 nm laser pulses at 10 Hz. In our study, 750 nm and 830 nm were used for PA functional imaging. We chose these two wavelengths for two reasons. First, deHb has stronger absorption at 750 nm, and Hb has stronger absorption at 830 nm\textsuperscript{26}. Second, the pulse energy of the OPO laser is still high at these two wavelengths. Good signal-to-noise can be achieved by comprehensively considering the above two factors. A time division multiplexing approach was employed to achieve PA/US real time imaging with two wavelengths and SO$_2$ mapping at a 5 Hz frame rate. Before calculating SO$_2$, PA signals of different wavelengths were normalized by laser energies recorded in real time. By scanning the probe across the breast skin surface (see Supplementary Movie S1), the system could perform local 3D dual-modal functional imaging (see Supplementary Fig. S2). During 3D image acquisition, the electric motor moved at a steady velocity (1 mm/s), while a group of 2D US images and PA images at two wavelengths was acquired at 0.2 mm step intervals with a total scanning length of 4 cm and total scanning time of 40 seconds. 3D imaging results were downloaded for further data analysis.

To render 3D PA/US images (see Supplementary Fig. S2), we imported the 2D SO$_2$ map into Amira (version 6.0. Visage Imaging) and obtained vessel networks by extracting the surface of the SO$_2$ map using pixels with SO$_2$ values larger than 40% and less than 100%. We chose 40% as a lower bound because previous studies have shown that SO$_2$ values in breast tumours normally do not go below 40%\textsuperscript{17,27,28}. Additionally, because the patients we enrolled were all at Stage 1, abnormal SO$_2$ values caused by necrosis would not be present in our study. Based on the above reasons, SO$_2$ values below 40% were not employed, as these were likely caused by system noise and unwanted PA signals from the probe itself. After vessels networks were obtained, the surface of the tumour region identified in B-mode was then coregistered with the vessel map at a certain degree of transparency.

Quantification analysis. In the near-infrared range, the dominant endogenous photoabsorber is haemoglobin, which can be either oxy-haemoglobin (Hb) or deoxy-haemoglobin (deHb)\textsuperscript{29}. PA signal with optical wavelength $\lambda$, at the spatial position $r$ can then be described according to Eq. (1)\textsuperscript{10}. $\Gamma$ is the Grüneisen parameter of the tissue. $F(\lambda,r)$ is the optical fluence with optical wavelength $\lambda$, at the spatial position $r$. $C(Hb, r)$ and $C(deHb, r)$ are the concentrations of Hb and deHb at $r$, respectively. $\varepsilon_{Hb}(\lambda)$ and $\varepsilon_{deHb}(\lambda)$ are the known molar extinction coefficients of Hb and deHb, respectively, at wavelength $\lambda$.

$$PA(\lambda, r) = TF(\lambda, r)(C(Hb, r)\varepsilon_{Hb}(\lambda) + C(deHb, r)\varepsilon_{deHb}(\lambda))$$

(1)

Because both the absorption coefficient $\mu(\lambda)$ and the reduced scattering coefficient $\mu_s’$ of the background breast tissue at 750 nm and 830 nm are similar\textsuperscript{13,31}, the optical fluence $F(\lambda_{750nm}, r)$ and $F(\lambda_{830nm}, r)$ were assumed to be approximately the same in our study after normalization with laser illumination power at each wavelength. The definition of oxygenation saturation (SO$_2$) is as follows,

$$SO_2(r) = C(Hb, r)/(C(Hb, r) + C(deHb, r))$$

(2)
Then, the SO2 at each pixel can be derived from two PA values at two different wavelengths, as shown in Eq. (3). Any pixels with negative calculated SO2 values were removed from the latter analysis.

$$SO2(r) = \frac{PA(\lambda_{750nm}, r) \varepsilon_{\text{deHb}}(\lambda_{830nm}, r) - PA(\lambda_{430nm}, r) \varepsilon_{\text{Hb}}(\lambda_{750nm})}{PA(\lambda_{750nm}, r) \varepsilon_{\text{deHb}}(\lambda_{830nm}, r) - \varepsilon_{\text{Hb}}(\lambda_{830nm}, r) + PA(\lambda_{430nm}, r) \varepsilon_{\text{deHb}}(\lambda_{750nm}) - \varepsilon_{\text{deHb}}(\lambda_{750nm})}$$ (3)

3D quantification analysis was then carried out in both tumour and tumour surrounding regions. The 3D tumour outer boundary was rendered based on series of 2D tumour contours marked by experienced physicians. The principle of delineation is to identify the tumour boundary where there is the highest grey scale contrast. After obtaining the 3D tumour outer boundary, we calculated the least volume ellipse (LVE) enclosing the 3D tumour region automatically in MATLAB (MathWorks, Inc.)14. This method has been verified to semi-automatically estimate tumour volume in CT35. The analysis process was repeatable due to the uniqueness of LVE enclosing the 3D tumour region. By extending each of three axis lengths of LVE 1.2 times, we obtained an extension ellipse. We defined the region inside the extension ellipse excluding the tumour region as the surrounding region (see Supplementary Fig. S3).

After labelling regions of interest, we calculated SO2 pixel average values in both regions, and a lower threshold of 40% was set to minimize artifacts. Similarly, we also calculated SO2 pixel average values in symmetrical locations in lateral normal breasts.

Patients and imaging procedure. Forty-five patients with breast tumours smaller than 2 cm and receiving a BIRADS rating from 3 to 5 with indication for surgery or biopsy were consecutively recruited from the outpatient and inpatient breast surgery department of Peking Union Medical College Hospital from November 2017 to January 2018. All patients went through imaging examinations via US and/or X-ray mammography, as well as MRI, by experienced radiologists. A conventional US examination was performed on all patients by 3 radiologists with more than 10 years of experience with breast US diagnosis. Only patients with clear tumour boundaries under US imaging were enrolled in our studies. 2D and 3D PA/US dual modality images were examined after conventional US. Biopsy and surgical resection were performed on all of the enrolled patients (patients graded with BIRADS 3 were all found to have an increasing tumour size in follow-up visits before biopsy). Pathological diagnoses were confirmed afterwards.

Of these forty-five patients, two patients were not imaged successfully due to system malfunctions; for another two patients, from US images, the distal margin depth of the breast lesions was more than 3.5 cm from the skin, which was beyond the effective imaging depth of the current system due to the strong light attenuation in tissue.

Of the remaining 41 patients, 17 either had an intraductal lesion or distal metastases, 16 were T1 stage invasive breast cancers (IBCs) without distal metastases, and 8 were either breast fibroma or breast adenosis. The results for intraductal lesions will be investigated in a different study to reduce confounding caused by the inherent pathogenesis difference between ductal carcinoma in situ (DCIS) and invasive breast cancer26. Results of lesions with distal metastases are also not included due to the focus on early breast cancer detection of this study.

The results for the measurements on the remaining 16 T1 stage IBCs, 8 benign lesions (six fibromas and two breast adenosis) as well as 22 contralateral healthy breasts (14 from patients with T1 stage IBCs, 8 from patients with benign lesions) were studied in this work. Two contralateral breasts were excluded because there were lesions inside. Detailed information on these 24 patients is listed in Supplementary Table S1. Each image of lesions (benign, malignant or healthy) was treated as one sample. Samples were grouped into three categories: benign group (either fibromas or breast adenosis, n = 8), malignant group (T1 stage IBCs, n = 16) and normal group (contralateral healthy breasts, n = 22).

To further reduce confounding effects of tumour sizes, we performed subgroup analyses based on results from tumours with similar sizes and similar numbers (8 malignant tumours and 8 benign tumours with similar sizes in each subgroup analysis). Information on tumour sizes and corresponding tumour numbers in the subgroups is summarized in Supplementary Table S2. To match malignant tumours and benign tumours with a size ranging from 1.6 to 2 cm, two out of ten malignant tumours with a size from 1.6 to 2 cm were included in each subgroup analysis. We repeated this procedure 45 times to cover all of the combinations.

Statistical analysis. We used the nonparametric two-tailed Mann-Whitney U-test to calculate the statistical significance between two groups, and a P value of 0.05 was considered to indicate 95% statistical significance. The Hodges-Lehmann estimator was used to determine the difference between two groups and the 95% confidence interval. Statistical analysis was performed with MATLAB (MathWorks, Inc.).

Results. Results from 24 patients (16 T1 stage IBCs, 8 benign lesions and 22 contralateral healthy breasts) in the imaging study are shown in Figs. 1–2. There were 22 contralateral healthy breasts instead of 24 because all but 2 patients had lesions (either benign or malignant) in one breast only while the other breast was healthy. As shown in Fig. 1a, in tumour regions, the SO2 volumetric mean value of the malignant group was 7.7% lower (95% confidence interval: 2.1%, 12.4%) than that of the benign groups (P = 0.016) and was 3.9% lower (95% confidence interval: 2.2%, 5.5%) than the normal group (P = 0.010). In tumour surrounding regions (Fig. 1b), the SO2 volumetric mean value of the malignant group was 4.9% lower (95% confidence interval: 1.6%, 8.4%) than that of the benign group (P = 0.009). Differences in SO2 volumetric mean values between the benign group and normal group were not significant at the 95% level.
From all 45 subgroup analyses with control of tumour size distribution, SO2 volumetric mean values in both tumour regions and tumour surrounding regions were significantly lower in malignant tumours than in benign tumours. In tumour regions, the SO2 volumetric mean value of the malignant group was at least 7.0% lower (95% confidence interval: 1.4%, 14.0%) than that of the benign group (0.005 ≤ P ≤ 0.028). In tumour surrounding regions, the SO2 volumetric mean value of the malignant group was at least 4.0% lower (95% confidence interval: 0.5%, 9.3%) than that of the benign group (0.010 ≤ P ≤ 0.028).

Receiver operating characteristic (ROC) curves for differentiating malignant tumours from benign tumours were plotted by varying the SO2 thresholds both inside tumours (Fig. 2a) and in tumour surrounding regions (Fig. 2b). With a cut-off value of 78.2% for the SO2 value inside tumours, we obtained a sensitivity of 100% and a specificity of 62.5%. The area under the ROC curve (AUC) was 0.81. With a cut-off value of 77.9% for the SO2 value in tumour surrounding regions, we obtained a sensitivity of 100%, a specificity of 75% and an AUC of 0.84.

Similarly, for all 45 subgroup analyses with control of tumour size distribution, with a cut-off value of 78.2% for the SO2 value inside tumours, we obtained an average sensitivity of 100%, an average specificity of 62.5% and an average AUC of 0.84. With a cut-off value of 77.9% for the SO2 value in tumour surrounding regions, we obtained an average sensitivity of 100%, an average specificity of 62.5% and an average AUC of 0.85.

**PA/US images of breast tumours.** Examples of invasive breast cancers and benign breast lesions are provided in Figs. 3–5. Figure 3a,b depict the SO2/US fused imaging results of a malignant tumour (IBC) and a benign...
tumour (fibroadenoma), respectively. Color scale bars of SO2 are shown to the left of the imaging results. Lower SO2 values were observed in and surrounding the malignant tumour (Fig. 3a), which indicates a pattern differing from that of benign lesions (Fig. 3b). For this malignant case, confidently grading the malignant tumour based on the US result was difficult because the tumour had a clear margin and a regular shape, which is similar to

Figure 3. 2D SO2/US imaging results of (a) an invasive breast cancer and (b) a breast fibroadenoma.

Figure 4. X-ray mammography results of the same (a) invasive breast cancer and (d) breast fibroadenoma shown in Fig. 3. CD31 immunochemistry (IHC) vascular staining results of the same (c) invasive breast cancer and (d) breast fibroadenoma shown in Fig. 3; both the tumour (thick brown arrow) and the surrounding area are depicted (thin brown arrow).
benign tumours. In addition, X-ray mammography and CD31 immunochemistry (IHC) vascular staining results are shown in Fig. 4. From the X-ray results in Fig. 4a, the malignant tumour could hardly be detected since there was no obvious calcification and clear margin. From the X-ray results in Fig. 4b, the benign tumour could not be defined as in the US. From IHC vascular staining results, more CD31 vascular staining showed up in and around the malignant tumour (Fig. 4c) than the benign one (Fig. 4d), which is consistent with the 2D PA/US imaging results.

Figure 5a,b show the 3D vascular network maps of the same tumours shown in Fig. 3a,b. A more abundant vascular network showed up in regions surrounding the malignant tumour (see Supplementary Movie S2), while substantially less vascular network was shown around the benign tumour (see Supplementary Movie S3). The probability density distributions of SO2 in tumour and tumour surrounding regions are also displayed (Fig. 5c,d). An obviously low intra-tumoral SO2 distribution was detected in the malignant tumour compared to that in the benign tumour.

Discussion
In this pilot clinical study, we presented 3D PA/US functional imaging on patients with small breast tumours (less than 2 cm). Based on the statistical results from 3D imaging data, invasive breast cancers showed obviously lower volumetric mean SO2 than both the benign group and the healthy group. With the SO2 cut-off value shown in the Statistical section, the sensitivity and specificity in differentiating T1 IBC and benign tumours were favourable. Conventional grey scale US has the advantage of clearly displaying the edge of breast tumours, even for some lesions that are not easily detected by X-ray, as shown previously in this study. With PA imaging added to grey scale US imaging, more functional information, such as haemoglobin imaging and SO2 distribution of the tumour, could potentially enhance the diagnostic confidence, especially in differentiating the malignant tumours from benign ones due to the difference in SO2 shown in PA/US dual mode imaging results.

Our result is consistent with a previous reported comparable clinical study in which more than 2000 breast tumours underwent handheld 2D PA/US functional imaging. The results found that SO2 exhibited a lower trend in malignant tumours than in benign ones. In another clinical study based on photoacoustic mammography (PAM), the SO2 level in malignant tumours was also found to be lower than in the counterpart contralateral normal breast region of interest, which was in agreement with the results of the present study.
The potential reasons for hypoxia in malignant tumours have been widely investigated\(^37\)–\(^39\), and hypoxia likely arises as a result of an imbalance between the supply and consumption of oxygen. One predominant causative factor of the imbalance is severe structural and functional abnormalities in the tumour microcirculation, such as a disorganized vascular network, including dilations and elongated and tortuous shape. Interestingly, in addition to the significant differences in \(\text{SO}_2\) inside tumours, we also found a significant difference in \(\text{SO}_2\) in tumour surrounding regions. Although the mechanism underlying this difference is not clear yet, based on previous breast contrast enhanced imaging studies, a peripheral enhancement region of breast tumours is closely related to malignancy\(^40\),\(^41\). Histological features related to peripheral enhancement region include the existence of viable cancer cells\(^42\), expression of vascular endothelial growth factor (VEGF), and high microvascular density\(^41\), which may potentially cause a lower \(\text{SO}_2\) in this region. In addition to the significant difference in \(\text{SO}_2\) between benign and malignant tumours, we noticed that there is a weak trend (although not a significant difference) in which benign tumours have higher \(\text{SO}_2\) values than normal tissues. Currently we have no clear interpretation of the underlying mechanism, but a similar trend was also found in another study\(^43\). One potential explanation is that there are more abundant arteries in benign tumours than in normal tissues\(^44\), which could cause higher \(\text{SO}_2\) in benign tumours.

Compared to 2D functional PA/US imaging\(^13\),\(^14\), 3D functional PA/US imaging is advantageous for several reasons. First, 3D PA/US imaging can provide quantified results based on 2D PA imaging, which may better present the overall functional imaging features of a tumour. To verify this, Fig. 6 displays the average \(\text{SO}_2\) values along different 2D slices within the tumour regions of a malignant case, showing that the \(\text{SO}_2\) values could largely vary from slice to slice, making it challenging to select an appropriate 2D slice as the representative image to calculate the \(\text{SO}_2\) for evaluation and diagnosis of the tumour. Second, compared to the scoring system employed in the previous 2D PA/US imaging study\(^13\), which is dependent on a manual scoring process, 3D quantification of the PAI physiological information may avoid intra-observer difference to a certain extent and thus deliver a diagnostic index with better repeatability and reliability. Third, 3D distribution of the vessel network could reveal more comprehensive spatial information on the tumoral vasculature than 2D distribution.

To date, there is no clear definition of tumour surrounding region. Some researchers defined thick echogenic rim surrounding some tumours as tumour surrounding regions\(^13\), while a thick echogenic rim doesn’t exist in every tumour, and it is hard to delineate the margin of the echogenic rim in some cases. In our study, we applied a consistent method to define the tumour surrounding regions (see Supplementary Fig. S3). Our method proved to be applicable to all tumours in our study, providing a repeatable and automatic analysis process without identifying tumour surrounding regions manually.

Our research does have some limitations. For instance, the “limited view” problem caused most of the reconstructed vessels to have an orientation that tended to be parallel with the scanning direction. However, our study implied that a valuable quantitative evaluation was still obtainable based on these “biased” reconstructed results. Besides, since it is hard to obtain an accurate optical fluence map, quantification of haemoglobin concentration is not currently available. Additionally, we noticed that after controlling the size distribution, there is a minor decrease in specificity when using \(\text{SO}_2\) in tumour surrounding regions as a biomarker to differentiate benign tumours from malignant tumours. One potential reason is that only two benign tumours with sizes from 1.6 cm to 2 cm is a small sample size. We also could not exclude the possibility that \(\text{SO}_2\) in tumour surrounding regions may be related to tumour size. The mechanism underlying this observation will be explored in the future with larger sample size, especially for benign tumours with larger tumour size. An increase of the overall sample size could also help further refine the cut-off value and improve the effectiveness of our quantification analysis. Therefore, although our analysis shows promising results for 3D PA/US functional imaging in terms of aiding the evaluation of breast tumours, both sensitivity and specificity should be further verified with a much larger sample size in the future.

Figure 6. Average \(\text{SO}_2\) variation curve within different slices of a malignant tumour.
In summary, 3D quantification analysis of oxygenation saturation level, especially in the peri-tumoral environment, shows promising results for the differentiation of benign tumours from malignant tumours in this study. Therefore 3D PA/US functional imaging demonstrates potential in the detection and diagnosis of breast tumours.

Received: 9 December 2019; Accepted: 27 April 2020;
Published online: 15 May 2020

References
1. Turkoz, F. P. et al. Association between common risk factors and molecular subtypes in breast cancer patients. Breast 22, 344–350 (2013).
2. Desantis, C. E. et al. Breast cancer statistics, 2015: Convergence of incidence rates between black and white women. CA Cancer J. Clin 66, 31–42 (2016).
3. Omega, T. et al. Breast cancer screening in an era of personalized regimens: a conceptual model and National Cancer Institute initiative for risk-based and preference-based approaches at a population level. Cancer 120, 2955–2964 (2015).
4. Carney, P. A. et al. Individual and combined effects of age, breast density, and hormone replacement therapy use on the accuracy of screening mammography. Ann. Intern. Med. 138, 168–175 (2003).
5. Thigpen, D., Kappler, A. & Brem, R. The Role of Ultrasound in Screening Dense Breasts: A Review of the Literature and Practical Solutions for Implementation. Diagnostics (Basel) 8, 20 (2018).
6. National Research Council. Mammography And Beyond: Developing Technologies For The Early Detection Of Breast Cancer. (ed. Pafiak, M., Nass, S. J., Henderson, I. C., Lashof, I. C.) 9–11 (The National Academies Press, 2001).
7. Zackrisson, S., Ven, S. M. W. Yvd & Gambhir, S. S. Light In and Sound Out: Emerging Translational Strategies for Photoacoustic Imaging. Cancer Res. 74, 979–1004 (2014).
8. Beard, P. Biomedical photoacoustic imaging. Interface Focus 1, 602 (2011).
9. Li, C. & Wang, L. V. Photoacoustic tomography and sensing in biomedicine. Phys. Med. Biol. 54, R59 (2009).
10. Vaupel, P., Kullimaki, F. & Okunieff, P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res. 49, 6449–6465 (1989).
11. Weidner, N., Semple, J. P., Welch, W. R. & Folkman, J. Tumor angiogenesis and metastasis—correlation in invasive breast carcinoma. N Engl J Med 324, 1–8 (1991).
12. Vaupel, P., Schlegner, K., Knoop, C. & Höckel, M. Oxygenation of human tumors: evaluation of tissue oxygen distribution in breast cancers by computerized O2-tension measurements. Cancer Res. 51, 3316 (1991).
13. Neuschler, E. I. et al. A Pivotal Study of Optoacoustic Imaging to Diagnose Benign and Malignant Breast Masses: A New Evaluation Tool for Radiologists. Radiology, 172228 (2017).
14. Becker, A. et al. Multispectral optoacoustic tomography of the human breast: characterisation of healthy tissue and malignant lesions using a hybrid ultrasound-optoacoustic approach. Eur. Radiol. 28, 602–609 (2017).
15. Lin, L. et al. Single-breath-hold photoacoustic computed tomography of the breast. Nat. Commun. 9, 2352 (2018).
16. Heijblom, M. et al. Visualizing breast cancer using the Twente photoacoustic mammoscope: What do we learn from twelve new patient measurements? Opt. Express 20, 11582–11597 (2012).
17. Fakharnejahi, E. et al. Clinical report on the first prototype of a photoacoustic tomography system with dual illumination for breast cancer imaging. Plos one 10, e0139113 (2015).
18. Kim, C., Erpelding, T. N., Jankovic, L., Pashley, M. D. & Wang, L. V. Deeply penetrating in vivo photoacoustic imaging using a clinical ultrasound array system. Biomed. Opt. Express 1, 278–284 (2010).
19. Kolkman, R. G. M., Brands, P. J., Steenbergen, W. & Leeuwen, T. G. Cv Real-time in vivo photoacoustic and ultrasound imaging. J. Biomed. Opt. 13, 3 (2008).
20. Yang, M. et al. Photoacoustic/ultrasound dual imaging of human thyroid cancers: an initial clinical study. Biomed. Opt. Express 8, 3449–3457 (2017).
21. Garcia-Uribe, A. et al. Dual-modality photoacoustic and ultrasound imaging system for noninvasive sentinel lymph node detection in patients with breast cancer. Sci. Rep. 5, 15748 (2015).
22. Nandy, S. et al. Evaluation of ovarian cancer: initial application of coregistered photoacoustic tomography and US. Radiology 289, 740–747 (2018).
23. Gateau, J., Caballero, M. A. A., Dima, A. & Ntizichristos, V. Three-dimensional optoacoustic tomography using a conventional ultrasound linear detector array: Whole-body tomographic system for small animals. Med. Phys. 40, 013302 (2013).
24. Fromheiser, M. P. et al. Real-time optoacoustic monitoring and three-dimensional mapping of a human arm vasculature. J. Biomed. Opt. 15, 021305 (2010).
25. Wang, Y. et al. In vivo three-dimensional photoacoustic imaging based on a clinical matrix array ultrasound probe. J. Biomed. Opt. 17, 061208 (2012).
26. Prahl, S. Tabulated Molar Extinction Coefficient for Hemoglobin in Water. Available at: https://omlc.org/spectra/hemoglobin/summary.html (1998).
27. Cheng, X. et al. Breast cancer detection by mapping hemoglobin concentration and oxygen saturation. Appl. Opt. 42, 6412–6421 (2003).
28. Grenstein, D. et al. Concentration and oxygen saturation of haemoglobin of 50 breast tumours determined by time-domain optical mammography. Phys. Med. Biol. 49, 1163 (2004).
29. Jacques, S. L. Optical properties of biological tissues: a review. Phys. Med. Biol. 58, R37 (2013).
30. Luke, G. P., Ven, N. S. & Emelianov, S. Y. Optical wavelength selection for improved spectroscopic photoacoustic imaging. Photoacoustics 1, 36–42 (2013).
31. Durdurkan, T. et al. Bulk optical properties of healthy female breast tissue. Phys. Med. Biol. 47, 2847 (2002).
32. Cerussi, A. E. et al. Sources of absorption and scattering contrast for near-infrared optical mammography. Acad. Radiol. 8, 211–218 (2001).
33. Luke, G. P. & Emelianov, S. Y. Label-free detection of lymph node metastases with US-guided functional photoacoustic imaging. Radiology 277, 435–442 (2015).
34. Todd, M. J. & Yildirim, E. A. On Khachiyan’s algorithm for the computation of minimum-volume enclosing ellipsoids. Discrete Appl. Math. 155, 1731–1744 (2007).
35. Tirumani, S. H. et al. Accuracy and feasibility of estimated tumour volumetry in primary gastric gastrointestinal stromal tumours: validation using semi-automated technique in 127 patients. Eur. Radiol. 26, 286–295 (2016).
36. Watanabe, T. et al. Ultrasound image classification of Ductal Carcinoma in Situ (DCIS) of the breast: analysis of 705 DCIS lesions. Ultrasound Med. Biol. 43, 918–925 (2017).
37. Vaupel, P. & Harrison, L. Tumor hypoxia: causative factors, compensatory mechanisms, and cellular response. Oncologist 9, 4–9 (2004).
38. Vaupel, P., Briest, S. & Höckel, M. Hypoxia in breast cancer: pathogenesis, characterization and biological/therapeutic implications. Wien Med Wochenschr 152, 334–342 (2002).
39. Vaupel, P., Kelleher, D. K. & Höckel, M. Oxygenation status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy. In Seminars in oncology 28, 29–35 (WB Saunders, 2001).
40. Liu, H., Jiang, Y.-X., Liu, J.-B., Zhu, Q.-L. & Sun, Q. Evaluation of breast lesions with contrast-enhanced ultrasound using the microvascular imaging technique: initial observations. Breast 17, 532–539 (2008).
41. Matsuabayashi, R., et al. Breast masses with peripheral rim enhancement on dynamic contrast-enhanced MR images: correlation of MR findings with histologic features and expression of growth factors. Radiology 217, 841–848 (2000).
42. Santamaria, G., et al. Radiologic and pathologic findings in breast tumors with high signal intensity on T2-weighted MR images. Radiographics 30, 533–548 (2010).
43. Hohenberger, P., Felgner, C., Haensch, W. & Schlag, P. M. Tumor oxygenation correlates with molecular growth determinants in breast cancer. Breast Cancer Res. Treat. 48, 97–106 (1998).
44. Madjar, H., Sauerbrei, W., Prömpeler, H. J., Wolfarth, R. & Gufler, H. Color Doppler and duplex flow analysis for classification of breast lesions. Gynecol. Oncol. 64, 392–403 (1997).

Acknowledgements
The authors would like to thank Mindray Bio-Medical Electronics Co., Ltd. for providing support in device development, along with Beijing Natural Science Foundation(JQ18023); the National Key Research and Development Program of China(2017YFE0104200); the National Natural Science Foundation of China(81421004, 81301268); Beijing Nova Program Interdisciplinary Cooperation Project(xjjc201812); International S&T Cooperation Program of China(2015DFA30440); Beijing Nova Program(Z13110700413063) for funding.

Author contributions
Y.J., C.L. and M.Y. conceived and designed the study. Li. Z. and F.Y. constructed the hardware system. Le. Z. and X.H. constructed the control program. F.Y. and Le. Z. developed the software system and the reconstruction algorithm. M.Y., Li. Z., F.Y., T.H., M.W., N.S., C.Z., Y.G., Y.W., R.Z. performed the experiments and clinical data collection. Li. Z. analyzed the data. J.L. guided the patient study. H.W. carried out the pathologic examination. Y.J. and C.L. supervised the study. All authors reviewed the manuscript.

Competing interests
The authors declare no competing interests.

Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41598-020-64966-6.

Correspondence and requests for materials should be addressed to C.L. or Y.J.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2020